S1P-S1PR3-RAS 通路促进 S1PR3hi TAL1+ T 细胞急性淋巴细胞白血病进展,并被 S1PR3 拮抗剂有效抑制
该研究通过多队列转录组与预后分析发现,S1PR3 在部分 TAL1+ T 细胞急性淋巴细胞白血病(T-ALL)中高表达(S1PR3hi TAL1+ T-ALL),且预后不良。TAL1-RUNX1 结合 S1PR3 基因增强子区上调其表达,S1P-S1PR3 部分通过激活 KRAS 信号促使 T-ALL 细胞快速生长。S1PR3 抑制剂 TY-52156 在 T-ALL 患者来源异种移植(PDX)小鼠模型中有效减缓白血病进展并延长 S1PR3hi TAL1+ T-ALL 异种移植小鼠的寿命。
要点
- S1PR3 在部分 TAL1+ T-ALL 中高表达,该亚组预后不良。
- TAL1-RUNX1 结合 S1PR3 基因增强子区上调 S1PR3 表达。
- TY-52156 在 PDX 小鼠模型中减缓 S1PR3hi TAL1+ T-ALL 进展并延长寿命。
核心结论
- S1PR3 在 S1PR3hi TAL1+ T-ALL 中发挥重要致癌作用,可能是有前景的治疗靶点。
研究设计与样本
- 研究分析多个队列 T-ALL 的转录组与预后,采用药理学和遗传学方法,并在 T-ALL 患者来源异种移植(PDX)小鼠模型中评估 S1PR3 抑制剂 TY-52156。
主要发现
- S1PR3 在部分 TAL1+ T-ALL(S1PR3hi TAL1+ T-ALL)中高表达,该亚组预后不良。
- TAL1-RUNX1 通过结合 S1PR3 基因增强子区上调 S1PR3 表达。
- S1P-S1PR3 过度激活时 T-ALL 细胞快速生长,部分通过激活 KRAS 信号实现。
- TY-52156 在 PDX 小鼠模型中有效减缓白血病进展,并延长 S1PR3hi TAL1+ T-ALL 异种移植小鼠的寿命。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TAL1+ T-cell acute lymphoblastic leukemia (T-ALL) is a distinct subtype of leukemia with poor outcomes. Through the cooperation of co-activators, including RUNX1, GATA3, and MYB, the TAL1 oncoprotein extends the immature thymocytes with autonomy and plays an important role in the development of T-ALL. However, this process is not yet well understood. Here, by investigating the transcriptome and prognosis of T-ALL from multiple cohorts, we found that S1PR3 was highly expressed in a subset of TAL1+ T-ALL (S1PR3hi TAL1+ T-ALL), which showed poor outcomes. Through pharmacological and genetic methods, we identified a specific survival-supporting role of S1P-S1PR3 in TAL1+ T-ALL cells. In T-ALL cells, TAL1-RUNX1 up-regulated the expression of S1PR3 by binding to the enhancer region of S1PR3 gene. With hyperactivated S1P-S1PR3, T-ALL cells grew rapidly, partly by activating the KRAS signal. Finally, we assessed S1PR3 inhibitor TY-52156 in T-ALL patient-derived xenografts (PDXs) mouse model. We found that TY-52156 attenuated leukemia progression efficiently and extended the lifespan of S1PR3hi TAL1+ T-ALL xenografts. Our findings demonstrate that S1PR3 plays an important oncogenic role in S1PR3hi TAL1+ T-ALL and may serve as a promising therapeutic target.
引用
- Zhu D, Jiang T, Ma D, et al. S1P-S1PR3-RAS promotes the progression of S1PR3hi TAL1+ T-cell acute lymphoblastic leukemia that can be effectively inhibited by an S1PR3 antagonist. Leukemia. 2023. PMID: 37591940. doi:10.1038/s41375-023-02000-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。